158 related articles for article (PubMed ID: 30766562)
1. CA 125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding.
Nithin KU; Sridhar MG; Srilatha K; Habebullah S
Afr Health Sci; 2018 Dec; 18(4):972-978. PubMed ID: 30766562
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of tumour markers in endometrial cancer.
Lo SS; Cheng DK; Ng TY; Wong LC; Ngan HY
Tumour Biol; 1997; 18(4):241-9. PubMed ID: 9218009
[TBL] [Abstract][Full Text] [Related]
3. [Clinical value of combined detection of serum human epididymal secretory protein E4 and CA(125) in the diagnosis of endometrial carcinoma].
Zhang AM; Zhang P
Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):125-8. PubMed ID: 22455745
[TBL] [Abstract][Full Text] [Related]
4. Is the measurement of placental protein-14 and CA-125 in plasma and uterine flushings useful in the evaluation of peri-menopausal and post-menopausal bleeding?
Li TC; Okon MA; Dalton CF; Heatley M; Laird SM
Hum Reprod; 1998 Oct; 13(1O):2895-901. PubMed ID: 9804252
[TBL] [Abstract][Full Text] [Related]
5. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
6. [Value of (18)F-FDG imaging and serum tumor markers in the diagnosis of recurrent endometrial carcinoma].
Wang Q; Hong L; Wang JL; Yue MG; Li HB; Li Y
Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):300-3. PubMed ID: 20510085
[TBL] [Abstract][Full Text] [Related]
7. Endometrial cancer and hyperplasia rate in women before menopause with abnormal uterine bleeding undergoing endometrial sampling.
Gawron I; Łoboda M; Babczyk D; Ludwin I; Basta P; Pityński K; Ludwin A
Przegl Lek; 2017; 74(4):139-43.. PubMed ID: 29696944
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of tumour specific growth factor (TSGF) and carbohydrate antigen-125 (CA-125) in carcinoma of the endometrium.
Yu B; Xu PZ; Wang QW; Zhou H; Zhou HX
J Int Med Res; 2009; 37(3):878-83. PubMed ID: 19589273
[TBL] [Abstract][Full Text] [Related]
10. Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer.
Knific T; Osredkar J; Smrkolj Š; Tonin I; Vouk K; Blejec A; Frković Grazio S; Rižner TL
Gynecol Oncol; 2017 Oct; 147(1):126-132. PubMed ID: 28735628
[TBL] [Abstract][Full Text] [Related]
11. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
[TBL] [Abstract][Full Text] [Related]
12. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
13. Adiponectin to leptin index as a marker of endometrial cancer in postmenopausal women with abnormal vaginal bleeding: an observational study.
Nowosielski K; Pozowski J; Ulman-Włodarz I; Romanik M; Poręba R; Sioma-Markowska U
Neuro Endocrinol Lett; 2012; 33(2):217-23. PubMed ID: 22592205
[TBL] [Abstract][Full Text] [Related]
14. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
15. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
Yang J; Tang A; Ma J; Sun X; Ming L
Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
[TBL] [Abstract][Full Text] [Related]
16. Abnormal uterine bleeding and prognosis of endometrial cancer.
Kimura T; Kamiura S; Yamamoto T; Seino-Noda H; Ohira H; Saji F
Int J Gynaecol Obstet; 2004 May; 85(2):145-50. PubMed ID: 15099776
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of tumor markers in southern Indian breast cancer patients.
Porika M; Malotu N; Veldandi UK; Yadala N; Abbagani S
Asian Pac J Cancer Prev; 2010; 11(1):157-9. PubMed ID: 20593949
[TBL] [Abstract][Full Text] [Related]
18. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin.
Yurkovetsky Z; Ta'asan S; Skates S; Rand A; Lomakin A; Linkov F; Marrangoni A; Velikokhatnaya L; Winans M; Gorelik E; Maxwell GL; Lu K; Lokshin A
Gynecol Oncol; 2007 Oct; 107(1):58-65. PubMed ID: 17659325
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance.
Hing JX; Mok CW; Tan PT; Sudhakar SS; Seah CM; Lee WP; Tan SM
Breast; 2020 Aug; 52():95-101. PubMed ID: 32485607
[TBL] [Abstract][Full Text] [Related]
20. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer.
Jiang T; Huang L; Zhang S
BMC Cancer; 2015 May; 15():396. PubMed ID: 25964114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
